查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014281

心臟麻痹治療市場：按治療方法、年齡層、分銷管道和最終用戶分類的全球市場預測 – 2026-2032 年

Cardiac Arrest Treatment Market by Treatment Type, Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年心臟麻痹治療市場價值為 256.3 億美元，預計到 2026 年將成長至 277 億美元，複合年成長率為 9.54%，到 2032 年將達到 485.3 億美元。

主要市場統計數據
基準年 2025 256.3億美元
預計年份：2026年 277億美元
預測年份：2032年 485.3億美元
複合年成長率 (%) 9.54%

全面介紹心臟麻痹治療的現狀，重點在於臨床緊迫性、創新促進因素、相關人員的角色以及系統層面的實施重點。

心臟麻痹是急診系統中時間緊迫且預後影響最大的疾病之一，而臨床、技術和政策領域的最新進展正在重塑醫療服務的提供方式。生存率取決於整個“生存鏈”，從快速識別和公共急救到最佳化的院前干預、先進的院內治療以及復甦後護理。因此，急診醫療服務、醫院、門診中心和居家照護等相關人員在重新審視臨床路徑、採購重點、人員能力和技術投資，以改善神經系統預後並降低可預防的死亡率。

技術、臨床和營運方面的變革正在重新定義心臟麻痹護理的提供、緊急應變的整合以及可衡量的生存管道。

心臟麻痹救治正經歷著一場變革，這得益於醫療設備工程、數位醫療和系統為基礎的緊急應變設計的進步。機械胸外按壓系統正變得更加模組化，更便於現場部署，即使在惡劣環境和長時間轉運過程中也能持續提供高品質的按壓。同時，去心房顫動技術也在不斷發展，出現了穿戴式解決方案和更智慧的自動體外心臟去心房顫動（AED），這些設備融合了演算法節律分析和即時指導功能，已被民用救援人員廣泛使用。除了這些設備層面的改進之外，與二氧化碳監測和連續心電圖（ECG）等監測技術的整合也日益緊密。這使得臨床醫生能夠即時獲得關於灌注和節律的回饋，從而能夠更快地調整治療方案，並使其更加基於實證醫學。

對 2025 年美國關稅環境及其對供應鏈韌性、籌資策略、製造本地化和醫療設備。

美國2025年推出的關稅政策為心臟麻痹急救技術領域的採購、庫存計劃以及與跨境供應商的關係帶來了新的複雜性。影響醫療設備、電子元件及相關耗材的關稅措施正直接衝擊整個供應鏈的成本結構，影響製造商的採購決策，並促使醫院和急救醫療服務（EMS）採購團隊重新評估供應商協議和合約保護條款。由於關稅增加了某些進口組件和成品的接收成本，製造商被迫重新考慮零件來源，探索替代生產區域，或在短期內承擔成本，同時在其他環節最大限度地提高效率。

詳細的細分洞察揭示了治療方法類型、最終用戶環境、分銷管道和年齡層如何共同影響採用、培訓和採購趨勢。

對細分市場的深入理解揭示了不同治療方法和醫療環境如何相互作用，從而影響臨床路徑、應用趨勢和採購行為。就治療類型而言，設備種類繁多，從手動和機械心肺復甦系統到各種去心房顫動方案，每類設備都有其獨特的臨床和操作權衡。機械胸外按壓技術（例如負荷分配帶、活塞驅動系統、氣動背心等）旨在解決在長時間復甦和轉運過程中維持高品質按壓的難題，其應用往往與系統資源、方案標準化和培訓能力密切相關。去心房顫動技術包括自動體外心臟去心房顫動(AED)、植入式心臟整流去顫器和穿戴式去心房顫動解決方案。這些設備適用於不同的應用場景，從公共場所突發心臟麻痹到慢性風險管理，需要不同的部署模式和維護方法。

美洲、歐洲、中東和非洲以及亞太地區在採納、監管、生產能力和臨床服務提供方面的主要區域觀點。

區域因素對心臟麻痹治療技術的監管管道、服務提供模式和商業策略有顯著影響。在美洲，完善的院前急診系統和大規模醫院網路為先進醫療設備的應用、監測技術的整合以及循證方案的實施創造了有利條件。在北美醫療機構中，與電子健康記錄的互通性、急救醫療服務（EMS）與醫院之間的協作工作流程以及高級臨床培訓往往備受重視。同時，採購流程的複雜性以及與保險公司的談判也影響著人們對產品配置選擇和售後支援的預期。

企業策略行動和產品定位強調主要供應商之間的產品組合多元化、服務擴展、製造韌性和基於證據的夥伴關係。

在心臟麻痹治療領域營運的公司正致力於實現多項相互交織的策略目標，以維持成長並維持臨床影響力。產品組合多元化至關重要。成功的公司正在平衡對耐用醫療設備、一次性耗材、療法和數位化服務的投資，從而為醫院和急救醫療服務 (EMS) 系統打造整合的價值提案。與急救醫療服務提供者、學術機構和契約製造製造商建立策略夥伴關係關係是加速產品開發、臨床檢驗和分銷網路拓展的常用方法。許多主要企業也在拓展其服務範圍，例如培訓、維護和遠端監測，以建立長期合作關係並展示真實的臨床成果。

為幫助產業領導者增強韌性、加快臨床部署和最佳化所有醫療保健環境中的經營模式提供切實可行的策略建議。

行業領導企業需要採取果斷行動，將技術潛力轉化為永續的臨床和商業性影響。首先，透過近岸外包、多源採購策略或長期供應商合約等方式投資於供應鏈韌性和靈活的製造能力，可以降低因專案實施而導致的成本衝擊和物流瓶頸風險。其次，優先考慮設備和監測系統之間的互通性和數據標準，可以改善臨床工作流程，並支援院前和院內環境中的結果評估。第三，將臨床證據的創建（例如真實世界註冊研究和與醫療保健系統的合作測試）納入產品藍圖，有助於制定報銷策略並促進臨床醫生採納。

調查方法的透明度：本節概述了得出本報告結論的主要研究訪談、臨床證據整合、監管審查和檢驗程序。

本報告的研究結果和見解是基於一項多方面的研究途徑，強調三角驗證和透明度。主要研究包括對醫療保健專業人員、急救醫療服務 (EMS) 管理人員、採購負責人和行業高管進行結構化訪談，以了解他們對設備效用、培訓需求和採購挑戰的第一手觀點。除了這些定性資訊外，我們還廣泛查閱了同行評審的臨床文獻、專業協會指南、監管申報文件和技術規範，以確保對設備和治療方法方案的分析基於最新證據。在條件允許的情況下，我們還參考了上市後監測數據和臨床註冊信息，以檢驗性能聲明並了解醫療機構中的部署模式。

為了指導心臟麻痹治療的策略規劃和臨床實踐，我們整合了考慮技術趨勢、政策影響和相關人員責任的結論。

目前，心臟麻痹治療正處於轉折點，技術創新、政策壓力和不斷發展的服務模式相互交織，重新定義臨床實踐。機械輔助和去心房顫動技術、先進的監測手段以及精細的治療方法共同作用，使得在整個生命保障鏈中能夠進行更一致、數據驅動的干涉措施。然而，這些進步取決於實施和維護這些系統的有效性。為了將創新轉化為更好的患者預後，採購流程、培訓項目、監管政策的清晰度和供應鏈的韌性同樣至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章心臟麻痹治療市場：依治療方法分類

  • 心肺復甦裝置
    • 負載分配帶裝置
    • 活塞驅動裝置
    • 氣動背心裝置
  • 去心房顫動
    • 自動體外心臟去心房顫動
    • 植入式心臟整流去顫器
    • 去心房顫動
  • 藥物治療
  • 低溫療法系統
  • 監控系統
    • 二氧化碳測量儀系統
    • 心電圖監測儀

第9章：心臟麻痹治療市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第10章：心臟麻痹治療市場：依分銷管道分類

  • 離線
  • 線上

第11章：心臟麻痹治療市場：以最終用戶分類

  • 門診部
  • 緊急醫療服務
  • 居家照護
  • 醫院

第12章心臟麻痹治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：心臟麻痹治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：心臟麻痹治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國心臟麻痹治療市場

第16章：中國心臟麻痹治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • BIoTronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Edwards Lifesciences Corporation
  • GE HealthCare Technologies Inc.
  • Johnson & Johnson
  • Koninklijke Philips NV
  • LivaNova PLC
  • Medtronic, Inc.
  • Nihon Kohden Corporation
  • Siemens Healthineers AG
  • Stryker Corporation
  • Terumo Corporation
  • ZOLL Medical Corporation
Product Code: MRR-433AB1DC2886

The Cardiac Arrest Treatment Market was valued at USD 25.63 billion in 2025 and is projected to grow to USD 27.70 billion in 2026, with a CAGR of 9.54%, reaching USD 48.53 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 25.63 billion
Estimated Year [2026] USD 27.70 billion
Forecast Year [2032] USD 48.53 billion
CAGR (%) 9.54%

Comprehensive introduction to the cardiac arrest treatment landscape highlighting clinical urgency, innovation vectors, stakeholder roles, and system-level implementation priorities

Cardiac arrest represents one of the most time-sensitive and outcome-determinant conditions across acute care systems, and recent years have produced a convergence of clinical, technological, and policy developments that are reshaping how care is delivered. Survivability depends on the entire chain of survival, from rapid recognition and bystander response through optimized prehospital interventions, advanced in-hospital therapies, and post-resuscitation care. As a result, stakeholders across emergency medical services, hospitals, ambulatory centers, and home care are reassessing clinical pathways, procurement priorities, workforce competencies, and technology investments to improve neurological outcomes and reduce preventable mortality.

At the same time, innovation is accelerating along multiple vectors: mechanical CPR solutions, automated and implantable defibrillation technologies, refined pharmacologic protocols, targeted temperature management systems, and increasingly sophisticated monitoring equipment are all converging to change clinical decision-making in real time. These developments are accompanied by evolving regulatory expectations and a growing emphasis on interoperability and data capture, which together create both opportunities and operational challenges. Consequently, organizational leaders must balance near-term readiness for acute events with longer-term investments that support resilience, scale, and measurable improvements in patient outcomes.

Transformative technological, clinical, and operational shifts that are redefining cardiac arrest care delivery, emergency response integration, and measurable survival pathways

The cardiac arrest care landscape is undergoing transformative shifts driven by advances in device engineering, digital health, and systems-based emergency response design. Mechanical chest compression systems have become more modular and field-deployable, enabling consistent high-quality compressions in challenging environments and during prolonged transport. Concurrently, defibrillation technologies are branching into more diverse formats, with wearable solutions and smarter automated external defibrillators that incorporate algorithmic rhythm analysis and real-time guidance for lay responders. These device-level improvements are complemented by tighter integration of monitoring technologies such as capnography and continuous ECG, which provide clinicians immediate feedback on perfusion and rhythm, enabling faster, evidence-based therapeutic adjustments.

In parallel, drug therapy protocols are being refined through iterative clinical research, and targeted temperature management systems have seen both technological and procedural optimization to reduce secondary neurologic injury. Digital transformation and data-driven practices are promoting early-warning and dispatch optimization through telemedicine platforms and predictive analytics, thereby improving response times and coordination between bystanders, EMS, and receiving facilities. Finally, training paradigms are evolving to emphasize multi-disciplinary simulation, community readiness, and remote education, which together create a more resilient emergency response ecosystem. These shifts are redefining the metrics of success-and drawing attention to interoperability, clinician workflow alignment, and demonstrable patient outcomes as the core criteria for adoption.

Cumulative assessment of the 2025 United States tariff environment and its implications for supply chain resilience, procurement strategy, manufacturing localization, and device access

The tariff environment introduced by the United States in 2025 has introduced a new layer of complexity into procurement, inventory planning, and cross-border supplier relationships for cardiac arrest technologies. Tariff actions that affect medical devices, electronic components, and ancillary supplies have immediate implications for cost structures across the supply chain, influencing manufacturer sourcing decisions and prompting procurement teams at hospitals and EMS services to reassess vendor agreements and contractual protections. As tariffs increase the landed cost of certain imported assemblies and finished goods, manufacturers are incentivized to revisit their component sourcing, consider alternate production geographies, or absorb costs in the short term while seeking efficiencies elsewhere.

In response, several tactical behaviors have emerged. First, original equipment manufacturers and smaller suppliers are accelerating nearshoring and expanding domestic assembly capabilities to mitigate exposure to trade policy volatility. Second, strategic inventory practices, including longer replenishment cycles and buffer stock for critical consumables, are more commonly being adopted, albeit at the expense of working capital. Third, procurement teams are renegotiating total-cost-of-ownership clauses to capture duties and logistical surcharges in supplier commitments. These adjustments are not merely financial; they shape innovation trajectories by influencing which product configurations are commercially viable within constrained cost envelopes.

Regulatory and reimbursement landscapes interact with tariff effects to determine net commercial impact. Where tariffs increase device prices, payers and public purchasers may pressure manufacturers to justify cost increases through demonstrable clinical benefit and long-term cost offsets. Conversely, tariffs have created opportunities for domestic manufacturers and contract manufacturers to expand capacity, attracting investment aimed at ensuring continuity of supply. Finally, the policy environment itself is dynamic: stakeholders must continuously monitor tariff adjustments, exemptions for medical goods, and trade negotiations to anticipate mid-cycle shocks and plan capital investments accordingly. From a strategic perspective, resilience through diversified sourcing and contractual clarity has become as essential as product innovation in safeguarding access to critical cardiac arrest technologies.

Deep segmentation insights revealing how treatment modality categories, end-user settings, distribution channels, and age cohorts collectively shape adoption, training, and procurement dynamics

A nuanced understanding of segmentation reveals how different treatment modalities and care settings interact to shape clinical pathways, adoption dynamics, and procurement behavior. Within treatment types, devices range from manual and mechanical CPR systems to a spectrum of defibrillation options, and each category presents specific clinical and operational trade-offs. Mechanical chest compression technologies-whether load-distributing band devices, piston-driven systems, or pneumatic vest designs-address the challenge of sustained high-quality compressions in prolonged resuscitation or transport, and adoption tends to correlate with system resources, protocol standardization, and training capacity. Defibrillation spans automated external defibrillators, implantable cardioverter devices, and wearable cardioverter solutions; each fulfills distinct use cases from public-access sudden collapse to chronic risk management, requiring different deployment models and maintenance approaches.

Drug therapies remain a cornerstone of advanced cardiac life support, with agents such as amiodarone, epinephrine, and vasopressin occupying defined roles in rhythm management and hemodynamic support. These therapeutics interplay with device choices and temperature management strategies, with hypothermia systems-both endovascular and surface cooling-becoming integral to post-arrest care pathways that seek to preserve neurologic function. Monitoring systems such as capnography units and ECG monitors provide the clinical feedback necessary to titrate interventions in real time, reinforcing the role of integrated device ecosystems.

End-user segmentation further modulates demand and service requirements. Hospitals and emergency medical services are primary adopters of advanced devices and cooling systems and prioritize durability, service contracts, and clinician training. Ambulatory care centers and home care settings increasingly emphasize ease of use, remote monitoring capabilities, and patient-friendly wearables that support long-term risk management. Distribution channel dynamics are also pivotal: traditional offline procurement through medical distributors and group purchasing remains essential for institutional buyers, while online channels are growing for consumer-facing solutions and replenishable supplies due to convenience and broader product visibility. Age-group considerations-adult, geriatric, and pediatric-drive clinical protocol differentiation, device sizing, and drug dosing strategies, with pediatric applications often requiring specialized training and device adaptations. Taken together, segmentation illuminates where clinical need, procurement style, and regulatory obligations converge to influence adoption timing and investment priorities.

Key regional perspectives on adoption, regulation, manufacturing capacity, and clinical service delivery across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Geography materially influences regulatory pathways, service delivery models, and commercial strategies for cardiac arrest treatment technologies. In the Americas, established prehospital systems and large hospital networks create favorable conditions for advanced devices, integration of monitoring technologies, and adoption of evidence-based protocols. North American institutions frequently emphasize interoperability with electronic health records, coordinated EMS-hospital workflows, and high levels of clinical training. In parallel, procurement complexity and payer negotiations shape product configuration choices and post-market support expectations.

Across Europe, Middle East & Africa, regulatory harmonization within the European Union and contrasting regulatory architectures elsewhere create a mixed landscape. High-income European countries tend to adopt standardized clinical pathways and invest in public access defibrillation programs, while Middle Eastern healthcare markets often pursue rapid capacity expansion and advanced clinical capabilities. In parts of Africa, constrained resources and workforce shortages demand solutions that are low-maintenance, rugged, and cost-effective, creating opportunities for tailored devices and training initiatives.

The Asia-Pacific region exhibits substantial heterogeneity, driven by a mix of highly developed healthcare systems in some economies and rapidly upgrading infrastructure in others. Urbanization, expanding EMS networks, and digital health penetration are accelerating adoption in many parts of Asia-Pacific. Manufacturing capacity in the region also feeds global supply chains, which in turn affects sourcing decisions and regional procurement practices. Across all regions, demographic trends such as aging populations, the prevalence of cardiovascular risk factors, and differences in bystander CPR training rates shape the intensity and character of demand. Consequently, regional strategies must align product design, service models, and clinical engagement to local regulatory, economic, and workforce realities.

Strategic corporate behaviors and product positioning emphasizing portfolio diversification, service expansion, manufacturing resilience, and evidence-driven partnerships among leading providers

Companies operating in the cardiac arrest treatment space are pursuing several overlapping strategic priorities to sustain growth and clinical relevance. Portfolio diversification is central: successful firms balance investments across durable devices, disposable consumables, therapeutics, and digital services to create integrated value propositions for hospitals and EMS systems. Strategic partnerships with emergency care providers, academic centers, and contract manufacturers are commonly used to accelerate product development, clinical validation, and distribution reach. Many leading firms are also expanding service offerings-training, maintenance, and remote monitoring-to lock in long-term relationships and demonstrate real-world outcomes.

Manufacturing footprint and supply chain architecture are increasingly seen as competitive differentiators. Organizations with flexible production capabilities and multiple sourcing nodes are better positioned to absorb tariff shocks and logistic disruptions. Research and development investments continue to focus on miniaturization, sensor integration, algorithmic decision support, and ease of use for both lay rescuers and advanced clinicians. In addition, a growing number of companies are prioritizing outcomes-based evidence generation and post-market registries to document clinical impact and support reimbursement discussions. Strategic moves range from targeted acquisitions that add complementary technologies to collaborations that deliver bundled solutions for prehospital and post-resuscitation care. These corporate behaviors reflect a broader shift from transactional device sales toward service-oriented, evidence-driven commercial models that emphasize sustained clinical value.

Actionable strategic recommendations enabling industry leaders to strengthen resilience, accelerate clinical adoption, and optimize commercial models across care settings

Industry leaders must act decisively to translate technological promise into sustained clinical and commercial impact. First, investing in supply chain resilience and flexible manufacturing-whether through nearshoring, multi-sourcing strategies, or long-term supplier agreements-will reduce exposure to policy-driven cost shocks and logistical bottlenecks. Second, prioritizing interoperability and data standards across devices and monitoring systems will enhance clinical workflows and support outcome measurement across prehospital and in-hospital settings. Third, embedding clinical evidence generation into product roadmaps, including real-world registries and collaborative trials with healthcare systems, will strengthen reimbursement positioning and clinician adoption.

Fourth, deepening partnerships with EMS services and hospital networks through bundled service offerings, training programs, and performance-based contracts will increase the likelihood of sustained use and measurable outcomes. Fifth, targeting home care and ambulatory markets with user-centered device designs and remote-monitoring capabilities can capture new demand pathways while supporting continuity of care. Sixth, aligning pricing and contracting models with total-cost-of-care narratives-including demonstrating cost offsets from reduced neurologic disability-will help address payer scrutiny. Finally, leaders should develop agile regulatory and market-access strategies that anticipate regional variances and quickly operationalize compliance, ensuring that product introductions are timely and supported by appropriate clinician education and technical support.

Methodological transparency outlining primary research interviews, clinical evidence synthesis, regulatory review, and validation steps used to derive the report's conclusions

The findings and insights presented in this report are based on a multi-method research approach that emphasizes triangulation and transparency. Primary research included structured interviews with clinicians, EMS directors, procurement officers, and industry executives to capture frontline perspectives on device utility, training needs, and procurement challenges. These qualitative inputs were supplemented by an extensive review of peer-reviewed clinical literature, guidelines from professional societies, regulatory filings, and technical specifications to ground device and therapeutics analysis in contemporary evidence. Where available, post-market surveillance data and clinical registries were consulted to validate performance claims and to contextualize adoption patterns across care settings.

Analytical methodologies incorporated comparative product feature mapping, scenario analysis to examine supply chain sensitivities, and policy impact assessment focused on recent trade developments. Throughout the process, findings were iteratively validated with external clinical and industry experts to reduce bias and ensure relevance. Limitations are acknowledged: rapidly evolving regulatory decisions and emergent clinical studies can shift the evidence base, and localized procurement practices may create heterogeneity that requires customization of recommendations. Nevertheless, the methodological rigor-rooted in primary stakeholder engagement, systematic literature synthesis, and validation loops-supports actionable conclusions and pragmatic guidance for decision-makers.

Integrated conclusions synthesizing technological momentum, policy influences, and stakeholder responsibilities to guide strategic planning and clinical practice in cardiac arrest treatment

The cardiac arrest treatment landscape is at an inflection point where technological innovation, policy pressures, and service delivery evolution are converging to redefine clinical practice. Mechanical and defibrillation technologies, enhanced monitoring, and refined therapeutic approaches are collectively enabling more consistent, data-driven interventions across the entire chain of survival. Yet, these advancements are only as effective as the systems that deploy and sustain them; procurement practices, training programs, regulatory clarity, and supply chain resilience are equally critical to converting innovation into improved patient outcomes.

Looking forward, stakeholders must adopt integrated strategies that marry clinical evidence with operational readiness. Manufacturers should prioritize interoperable, service-oriented solutions and robust evidence generation. Providers and EMS systems will need to invest in training and integrated care pathways that translate device capabilities into measurable outcomes. Policymakers and payers must consider reimbursement and procurement frameworks that incentivize clinically proven technologies while ensuring equitable access. Taken together, coordinated action across these constituencies will determine the pace at which the promise of new cardiac arrest treatments produces durable improvements in survival and neurologic recovery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Arrest Treatment Market, by Treatment Type

  • 8.1. Cpr Devices
    • 8.1.1. Load Distributing Band Device
    • 8.1.2. Piston Driven Device
    • 8.1.3. Pneumatic Vest Device
  • 8.2. Defibrillator Devices
    • 8.2.1. Automated External Defibrillator
    • 8.2.2. Implantable Cardioverter Defibrillator
    • 8.2.3. Wearable Cardioverter Defibrillator
  • 8.3. Drug Therapies
  • 8.4. Hypothermia Systems
  • 8.5. Monitoring Systems
    • 8.5.1. Capnography Systems
    • 8.5.2. Ecg Monitors

9. Cardiac Arrest Treatment Market, by Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Cardiac Arrest Treatment Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Cardiac Arrest Treatment Market, by End User

  • 11.1. Ambulatory Care Center
  • 11.2. Emergency Medical Services
  • 11.3. Home Care
  • 11.4. Hospital

12. Cardiac Arrest Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cardiac Arrest Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cardiac Arrest Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cardiac Arrest Treatment Market

16. China Cardiac Arrest Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Biotronik SE & Co. KG
  • 17.7. Boston Scientific Corporation
  • 17.8. Cardinal Health, Inc.
  • 17.9. Edwards Lifesciences Corporation
  • 17.10. GE HealthCare Technologies Inc.
  • 17.11. Johnson & Johnson
  • 17.12. Koninklijke Philips N.V.
  • 17.13. LivaNova PLC
  • 17.14. Medtronic, Inc.
  • 17.15. Nihon Kohden Corporation
  • 17.16. Siemens Healthineers AG
  • 17.17. Stryker Corporation
  • 17.18. Terumo Corporation
  • 17.19. ZOLL Medical Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC ARREST TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIAC ARREST TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CARDIAC ARREST TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CARDIAC ARREST TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY LOAD DISTRIBUTING BAND DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY LOAD DISTRIBUTING BAND DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY LOAD DISTRIBUTING BAND DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PISTON DRIVEN DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PISTON DRIVEN DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PISTON DRIVEN DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PNEUMATIC VEST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PNEUMATIC VEST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PNEUMATIC VEST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AUTOMATED EXTERNAL DEFIBRILLATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AUTOMATED EXTERNAL DEFIBRILLATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AUTOMATED EXTERNAL DEFIBRILLATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY WEARABLE CARDIOVERTER DEFIBRILLATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY WEARABLE CARDIOVERTER DEFIBRILLATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY WEARABLE CARDIOVERTER DEFIBRILLATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CAPNOGRAPHY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CAPNOGRAPHY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CAPNOGRAPHY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ECG MONITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ECG MONITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ECG MONITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EMERGENCY MEDICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EMERGENCY MEDICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EMERGENCY MEDICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 152. GCC CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 153. GCC CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. G7 CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 176. G7 CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 177. G7 CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 178. G7 CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. G7 CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NATO CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 184. NATO CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 185. NATO CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. NATO CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. NATO CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES CARDIAC ARREST TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA CARDIAC ARREST TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)